Landos Biopharma, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Landos Biopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q1 2024.
  • Landos Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$8.9M, a 47.4% decline year-over-year.
  • Landos Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$24.8M, a 18.6% increase year-over-year.
  • Landos Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$21.9M, a 44.2% increase from 2022.
  • Landos Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$39.3M, a 2.22% decline from 2021.
  • Landos Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$38.4M, a 27.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$24.8M -$8.9M -$2.86M -47.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$21.9M -$6.12M -$887K -17% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$21M -$5.86M +$2.04M +25.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$23.1M -$3.92M +$7.36M +65.2% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-09
Q1 2023 -$30.4M -$6.03M +$8.83M +59.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$39.3M -$5.23M +$14.9M +74% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$54.1M -$7.9M +$4.71M +37.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$58.8M -$11.3M -$15.4M -375% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$43.5M -$14.9M -$5.05M -51.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$38.4M -$20.1M -$8.76M -77.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 -$29.7M -$12.6M -$4.37M -53.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$25.3M $4.1M +$8.87M Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$34.2M -$9.82M -$4.02M -69.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$30.1M -$11.3M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 -$8.23M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$4.78M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$5.8M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.